Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
暂无分享,去创建一个
M. Socinski | J. Siegfried | T. Burns | S. Dacic | A. Argiris | W. Gooding | L. Stabile | Jose Gomez-Garcia | D. Friedland | A. Tarhini | L. Villaruz | T. Floros | M. Farooqui | P. Tran | Autumn Gaither-Davis | D. Petro | Imran Rafique